Corticotropin-releasing hormone (CRH) antisense oligodeoxynucleotide induces anxiolytic effects in rat.
Antisense oligodeoxynucleotide complementary to the start coding region of rat corticotropin releasing hormone (CRH) mRNA was intracerebroventricularly infused into rats three times at 12-h intervals. In the shuttle-box avoidance procedure antisense-treated rats showed, within 6 h, significant acceleration and increase in the total number of discriminative avoidance responses compared with controls, treated with the corresponding sense probe or vehicle alone. Following the shuttle-box experiment hypothalamic CRH hybridization signals and immunoreactivity were reduced, while CRH immunoreactivity in the median eminence remained unchanged. Plasma ACTH and corticosterone were decreased in antisense-treated animals. It is likely that in addition to a selective blockade of CRH translation, antisense treatment may also interrupt secretion of CRH. Antisense targeting of the hypothalamo-hypophysial-adrenal axis may provide new strategies for the neuropharmacology of affective disorders.
Skutella
T
T
Max Planck Institute of Psychiatry, Clinical Institute, Munich, Germany.
Criswell
H
H
Moy
S
S
Probst
J C
JC
Breese
G R
GR
Jirikowski
G F
GF
Holsboer
F
F
D000818:Animals; D014151:Anti-Anxiety Agents / Q000494:pharmacology*; D001483:Base Sequence; D002552:Cerebral Ventricles; D003346:Corticotropin-Releasing Hormone / Q000235:genetics*; D007263:Infusions, Parenteral; D008297:Male; D008969:Molecular Sequence Data; D016376:Oligonucleotides, Antisense / Q000494:pharmacology*; D051381:Rats; D017207:Rats, Sprague-Dawley
D014151:Anti-Anxiety Agents; D016376:Oligonucleotides, Antisense; D003346:Corticotropin-Releasing Hormone